Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the bacteria infect the eyes. Infants are particularly susceptible, acquiring the infection from their mothers at birth. We have shown that the monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-irritating in ocular assays. Here we show that the physical and chemical properties of monocaprin make it ideal for use in a thickened eye drop formulation to combat eye infections. Monocaprin-containing formulations were assessed using analytical techniques and for antimicrobial activity in vitro and in ex vivo infections. Monocaprin-containing formulations retained activity after three years and are non-irritating, unlike preparations of povidone iodine in our assays. A recommended formulation for further development and investigation is 0.25% monocaprin in 1% HPMC with 1% polysorbate 20.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374094PMC
http://dx.doi.org/10.1038/s41598-020-68722-8DOI Listing

Publication Analysis

Top Keywords

eye drop
8
drop formulation
8
formulation combat
8
infections monocaprin-containing
8
monocaprin-containing formulations
8
monocaprin
4
monocaprin eye
4
combat antibiotic
4
antibiotic resistant
4
resistant gonococcal
4

Similar Publications

: Diabetes is a well-recognised factor inducing a plethora of corneal alterations ranging from dry eye to reduced corneal sensibility, epithelial defects, and reduced cicatrisation. This cohort study aimed to assess the efficacy of a novel ophthalmic solution combining cross-linked hyaluronic acid (CHA), chondroitin sulfate (CS), and inositol (INS) in managing diabetes-induced corneal alterations. Specifically, it evaluated the solution's impact on the tear breakup time (TBUT), the ocular surface disease index (OSDI), and corneal sensitivity after three months of treatment.

View Article and Find Full Text PDF

Improving Real-Time Feedback During Cochlear Implantation: The Auditory Nerve Neurophonic/Cochlear Microphonic Ratio.

Ear Hear

January 2025

Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.

Objectives: Real-time monitoring of cochlear function to predict the loss of residual hearing after cochlear implantation is now possible. Current approaches monitor the cochlear microphonic (CM) during implantation from the electrode at the tip of the implant. A drop in CM response of >30% is associated with poorer hearing outcomes.

View Article and Find Full Text PDF

Purpose: To evaluate the effects of mydriatics drops used primarily in routine eye examinations on the choroid tissue, which has a dense vascular network in the eye.

Methods: This prospective observational study included 90 eyes of 90 healthy children. Optical coherence tomography (OCT) images were obtained for all children before dilation.

View Article and Find Full Text PDF

The design of the prosthetic replacement of the ocular surface ecosystem (PROSE) device allows it to serve as a novel drug delivery system. In this article, we describe the off-label administration of amphotericin B and cenegermin by instillation in the PROSE device reservoir for the treatment of Candida keratitis in the setting of a persistent epithelial defect.

View Article and Find Full Text PDF

New treatments for glaucoma.

Curr Opin Ophthalmol

January 2025

New York Eye Surgery Center, New York City, New York, USA.

Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.

Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!